Advertisement
KTTA 外匯新聞
Pasithea Announces Receipt Of FDA Response Of Pre-IND Meeting For PAS-004 Clinical Development
Biotechnology company Pasithea Therapeutics Corp. (KTTA) announced Wednesday receipt of written responses to questions submitted for a Type 2 pre-Investigational New Drug Application (IND) meeting with the U.S. Food and Drug Administration (FDA) regarding clinical development plan for PAS-004.
RTTNews
|
616天前
